Radioligand therapy (RLT) is a targeted therapeutics option for a cancer treatment. Radiopharmaceutical is infused or injected into a peripheral vein.
Radioligand Therapy (RLT) Market: Introduction
- Radioligand therapy (RLT) is a targeted therapeutics option for a cancer treatment. Radiopharmaceutical is infused or injected into a peripheral vein. Ligands are labelled with radioactive isotopes, mostly beta-emitters, such as lutetium-177. High rate of long-lasting tumor remission and stabilization can be achieved using radioligand therapy (RLT).
Read Report Overview - https://www.transparencymarketresearch.com/radioligand-therapy-market.html
- Radioligand therapy (RLT) is a systemic therapy which is used in metastasized disease treatment. In radioligand therapies, radiopharmaceuticals bind to a tumor target.
- NET radioligand therapy is also known as peptide-receptor radionuclide therapy (PRRT). NET peptides targeting the somatostatin-receptor (SSTR) are used for treatment of neuroendocrine tumors.
- For prostate cancer treatment, radioligand specifically binds prostate-specific membrane antigen (PSMA). Prostate-specific membrane antigens (PSMA) are overexpressed in prostate cancer.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=74355
Key Drivers of Global Radioligand Therapy (RLT) Market
- The global radioligand therapy market is likely to be driven by increase in footprint of pharmaceutical manufacturers in potential markets in Asia Pacific, Latin America, and Middle East & Africa
- Research & development of radioligand therapy candidate to treat a broad range of cancer types is expected to propel the global radioligand therapy treatment market during the forecast period. Endocyte’s Lu-PSMA-617 is a radioligand therapy candidate which is currently under phase III clinical trial for treatment of prostate cancer.
- Increase in prevalence of cancer across the globe is expected to fuel the market growth during the forecast period. According to the American Cancer Society, in 2019, around 174,650 new cases for prostate cancer were diagnosed in the U.S.
Request for Analysis of COVID-19 Impact on Radioligand Therapy (RLT) Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=74355
- Strategic acquisition by leading players operating in radioligand therapy is helping manufacturers in expanding cancer product pipeline. Thus, approval and commercialization of pipeline products in the near future is expected to propel the market during the forecast period.
- In October 2018, Novartis underwent purchase agreement with Endocyte to purchase Endocyte’s Lu-PSMA-617 clinical product
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=74355
North America to Hold Major Share of Global Radioligand Therapy (RLT) Market
North America is projected to lead the market during the forecast period. North America is the leading market for radioligand therapy (RLT) driven by high rate of adoption of radioligand therapy products after FDA approval. According to Novartis, Lutathera has been prescribed to over 1,100 patients in the U.S.
Increase in awareness about the radioligand therapy and rise in patient base suffering from cancer in the U.S. are expected to drive the market in the region. Manufacturers are focused to enter into partnership with laboratories for research & development of radioligand therapy candidate which is anticipated to propel the market in the U.S.
Pre Book Radioligand Therapy (RLT) Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=74355<ype=S
Governments in Europe have favorable reimbursement policies. Furthermore, increase in research laboratories, rise in prevalence of cancer, and increase in funding provided by governments are anticipated to propel the market in the region during the forecast period.
Key Players Operating in Global Market
Major players operating in the global radioligand therapy market are:
- Novartis AG
- Johnson & Johnson Services, Inc.
- Pfizer Inc.
Browse More Trending Reports by Transparency Market Research:
Hemato Oncology Testing Market: https://www.transparencymarketresearch.com/hemato-oncology-testing-market.html
Artificial Muscle Fibers Market: https://www.transparencymarketresearch.com/artificial-muscle-fibers-market.html
Nano Antibodies Market: https://www.transparencymarketresearch.com/nano-antibodies-market.html
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/